http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022
-
Biodrain Medical (BIOR) to Present Preclinical Data on Oral Delivery of Biologics
-
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
-
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
-
Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference
-
Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference
-
Biodrain Medical, Inc. (BIOR) Issued Key Patent for Oral Delivery of GLP-1 Receptor Agonists
-
Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor Agonists
-
Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor Agonists
-
Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board
-
Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board
-
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference
-
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference
-
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Biodrain Medical, Inc. (BIOR) Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
-
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
-
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
-
Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update
-
Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update
-
Biora Therapeutics Announces Five Abstracts Accepted at American College of Gastroenterology Annual Scientific Meeting 2022
-
Biora Therapeutics Announces Five Abstracts Accepted at American College of Gastroenterology Annual Scientific Meeting 2022
-
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
-
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
-
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022
-
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022
-
Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics Platform
-
Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics Platform
-
Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
-
Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
-
Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis
-
Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis
-
Biora Therapeutics Shares Data Presented at Digestive Disease Week 2022
-
Biora Therapeutics Shares Data Presented at Digestive Disease Week 2022
-
Biora Therapeutics Announces New Patents for Targeted Therapeutics Platform
-
Biora Therapeutics Announces New Patents for Targeted Therapeutics Platform
-
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Global Investment Conference
-
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Global Investment Conference
-
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
-
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

